Offer - Urjas Oil for just ₹ 1 X
Cilasimune is a prescription drug, available for use as Injection. Other than this, Cilasimune has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Cilasimune is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
Besides the aforementioned side effects, there are other adverse effects of Cilasimune as well, which are listed below. Normally, these side effects of Cilasimune are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
Furthermore, you should know that effect of Cilasimune is Moderate for pregnant women and Moderate for women who are breastfeeding. Warnings related to Cilasimune's effects on the liver, heart and kidney, if any, have been listed below.
Cilasimune can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Cilasimune in conditions like Kidney Disease, Kidney Disease. Other conditions have been mentioned below in the Cilasimune contraindications section.
Additionally, Cilasimune may also adversely react with other medicines. Refer to the list below for further details.
In addition to these precautions, you may also note that Cilasimune is safe while driving, and is is addictive in nature.
Cilasimune is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Adult |
|
Geriatric |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Cilasimune safe for pregnant women?
Pregnant women may experience moderate side effects from Cilasimune. It is best to stop taking Cilasimune immediately and inform your doctor if you notice any discomfort.
Is the use of Cilasimune safe during breastfeeding?
If you are breastfeeding, you may experience some harmful effects of Cilasimune. In case you experience any of these, discontinue its use until you consult your doctor.
What is the effect of Cilasimune on the Kidneys?
Cilasimune may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cilasimune on the Liver?
Cilasimune may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cilasimune on the Heart?
Cilasimune has very mild side effects on the heart.
Cilasimune should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Cilasimune unless your doctor advises you to do so -
Is this Cilasimune habit forming or addictive?
No, you will not get addicted to Cilasimune.
Interaction between Food and Cilasimune
When consumed with certain foods, Cilasimune may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Cilasimune
Consumption of alcohol and Cilasimune together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Primaxin® (imipenem and cilastatin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 731
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 676-678